NGGT Inc., ("Next Generation Gene Therapeutics" or "NGGT"), a clinical-stage biotechnology company pioneering the next wave of gene therapy innovation for genetic rare diseases, today announced ...

as they show great promise for NGGT002 to serve as a safe and effective treatment for PKU," said Yiting Liu, Ph.D., VP of Translational Research at NGGT. "With our initial 40-week span of positive ...

"We are pleased with the results from our investigator-initiated trial, as they show great promise for NGGT002 to serve as a safe and effective treatment for PKU," said Yiting Liu, Ph.D., VP of ...

(“Next Generation Gene Therapeutics” or “NGGT”), a clinical-stage biotechnology company pioneering the next wave of gene therapy innovation for genetic rare diseases, today announced positive new data ...

Clinical Trial Success at Cincinnati Children's Supports Recent US FDA Approval for First Therapy to Directly Replace a Gene ...

Q3 2024 Earnings Call Transcript November 7, 2024 PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.39, ...

The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...

oral treatment for PKU. PKU is a genetic disease that manifests at birth and results from an inability to break down phenylalanine (phe), an amino acid that is commonly found in many foods.